ArticleFrontiers in pharmacology2021
Safety and Efficacy of Intravitreal Chemotherapy (Melphalan) to Treat Vitreous Seeds in Retinoblastoma.
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- In Vitro Stability and Preclinical Safety Evaluation of High-Dose Intravitreal Topotecan in Rabbits: Impact of Dose and Concentration.Ophthalmology science · 2026Article
- Stability study of topotecan in ophthalmic prefilled syringes for intravitreal delivery.European journal of hospital pharmacy : science and practice · 2025Article
- Targeting MCM6 Enhances Melphalan Chemosensitivity in Retinoblastoma by Modulating DNA Damage Response.Investigative ophthalmology & visual science · 2025Article
- Assessment of leachables in hospital pharmacy compounded topotecan conditioned in common off-label syringes for intravitreal use.Scientific reports · 2025Article
- Mimicking Retinoblastoma Treatment With Repeated Topotecan or Melphalan Develops Cross-Resistance to Classic Agents But Not to Repurposed Drugs.Investigative ophthalmology & visual science · 2024Article
- Advancements in Nanosystems for Ocular Drug Delivery: A Focus on Pediatric Retinoblastoma.Molecules (Basel, Switzerland) · 2024Review
- Advanced Interventional Treatments in Retinoblastoma Management: A Comprehensive Review.Cardiovascular and interventional radiology · 2024Review
- Risk factors for cataract in retinoblastoma management.The British journal of ophthalmology · 2024Article
- Pushing the limit: Globe salvage of Group D retinoblastoma with severe vitreous seeding with intra-arterial chemotherapy and 15 cycles of intravitreal chemotherapy.American journal of ophthalmology case reports · 2024Article
- Advancements in Retinoblastoma Treatment: Unraveling the Potential of Intravitreal Chemotherapy.Cureus · 2024Review
- Addition of intravitreal carboplatin with melphalan for management of vitreous seeding in retinoblastoma.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2023Article
- Sunitinib efficacy with minimal toxicity in patient-derived retinoblastoma organoids.Journal of experimental & clinical cancer research : CR · 2023Article
- Ocular and systemic toxicity of high-dose intravitreal topotecan in rabbits: Implications for retinoblastoma treatment.Experimental eye research · 2022Article
- Ultrasound Biomicroscopy Measurements of the Normal Thickness for the Ciliary Body and the Iris in a Middle East Population.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
- Spotlight on Targeted Chemotherapy in Retinoblastoma: Safety, Efficacy, and Patient Outcomes.OncoTargets and therapy · 2022Review
- New Therapeutic Perspectives in the Treatment of Uveal Melanoma: A Systematic Review.Biomedicines · 2021Review
- Toxicity to intravitreal melphalan in a patient with retinoblastoma.Romanian journal of ophthalmologyArticle
- Evolving trends in retinoblastoma management: A 16-year clinicopathological analysis of enucleated eyes.Taiwan journal of ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.